https://scholars.lib.ntu.edu.tw/handle/123456789/462213
標題: | Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients | 作者: | Lin Y.-. YI-HSIN LIANG JIA-HUEI TSAI JAU-YU LIAU JIN-TUNG LIANG BEEN-REN LIN JI-SHIANG HUNG LIANG-IN LIN LI-HUI TSENG YIH-LEONG CHANG KUN-HUEI YEH ANN-LII CHENG |
公開日期: | 2014 | 卷: | 9 | 期: | 2 | 來源出版物: | PLoS ONE | 摘要: | To identify better regimens in currently available chemotherapy would be beneficial to KRAS mutant metastatic colorectal cancer (mCRC) patients because they have fewer treatment options than KRAS wild-type mCRC patients. Clinicopathologic features and overall survival (OS) of KRAS mutant and wild-type mCRC patients who had used oxaliplatin-based, irinotecan-based, bevacizumab-based, as well as cetuximab-based regimens were compared to those who had never-used oxaliplatin-based, irinotecan-based, bevacizumab-based, as well as cetuximab-based regimens respectively. Between 2007 and 2012, a total of 394 mCRC patients, in whom 169 KRAS mutant and 225 KRAS wild-type, were enrolled. In KRAS mutant patients who had used oxaliplatin-based regimens (N = 131), the OS was significantly longer than that in KRAS mutant patients who had never-used oxaliplatin-based regimens (N = 38). The OS was 28.8 months [95% confidence interval (CI): 23.2-34.4] in KRAS mutant patients who had used oxaliplatin-based regimens versus 17.8 months [95% CI: 6.5-29.1] in KRAS mutant patients who had never-used oxaliplatin-based regimens (P = 0.026). Notably, OS in KRAS wild-type mCRC patients who had used oxaliplatin-based regimens (N = 185) was not significantly longer than that in KRAS wild-type mCRC patients who had never-used oxaliplatin-based regimens (N = 40) (P = 0.25). Furthermore, the OS in KRAS mutant patients who had used either irinotecan-based, bevacizumab-based or cetuximab-based regimens was not significantly different than that in KRAS mutant patients who had never-used either irinotecan-based, bevacizumab-based or cetuximab-based regimens respectively. In multivariate analyses, patients who had used oxaliplatin-based regimens remains an independent prognostic factor for longer OS in KRAS mutant mCRC patients. In conclusion, oxaliplatin-based regimens are more beneficial in KRAS mutant than in KRAS wild-type mCRC patients. ? 2014 Lin et al. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896861647&doi=10.1371%2fjournal.pone.0086789&partnerID=40&md5=a4bf69de2f692e455a223baa9f92fb57 https://scholars.lib.ntu.edu.tw/handle/123456789/462213 |
ISSN: | 1932-6203 | DOI: | 10.1371/journal.pone.0086789 | SDG/關鍵字: | bevacizumab; cetuximab; irinotecan; oxaliplatin; KRAS protein, human; oncoprotein; oxaliplatin; platinum complex; Ras protein; adult; aged; article; cancer prognosis; cancer survival; controlled study; drug use; female; gene mutation; human; major clinical study; male; metastatic colorectal cancer; oncogene K ras; overall survival; survival rate; survival time; treatment outcome; very elderly; wild type; young adult; Colorectal Neoplasms; drug administration; genetics; metastasis; middle aged; multivariate analysis; mutation; pathology; proportional hazards model; survival; time; tumor recurrence; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Proportional Hazards Models; Proto-Oncogene Proteins; ras Proteins; Survival Analysis; Time Factors; Treatment Outcome; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。